Galvani E et al. showed that a new type of irreversible EGFR-TKI CNX-2006 inhibited the cell proliferation via the NF-κB pathway, and was active against EGFR-mutated NSCLC models, both in vitro and in vivo [58]. Here, NFKB1 is linked to non-small cell lung carcinoma.